How trametinib works in lung cancer treatment

Trametinib (Trametinib), as a MEK inhibitor, has shown significant potential in the treatment of lung cancer, especially for patients with non-small cell lung cancer (NSCLC) carrying BRAF V600 mutations. BRAF V600 mutations are rare in lung cancer, accounting for about 1%-3%, but these patients often respond poorly to traditional chemotherapy. Trametinib inhibits the proliferation and survival of tumor cells by inhibiting MEK protein and blocking the RAS-RAF-MEK-ERK signaling pathway.

Clinical studies show that the combined treatment of trametinib and dabrafenibIn patients with advanced non-small cell lung cancer with BRAF V600E mutations, the objective response rate (ORR) can reach 63.9%-68.4%, the median progression-free survival (PFS) is significantly prolonged, and the overall survival (OS) of some patients even exceeds 29 months. This dual-target combination regimen not only improves the therapeutic effect, but also improves the patient's quality of life. However, the effectiveness of treatment varies from person to person and depends on the patient's genetic mutation status, pathological type and previous treatment history. Therefore, before using trametinib, it is necessary to confirm the BRAF V600 mutation through genetic testing, and develop a personalized treatment plan under the guidance of a professional doctor.

Although trametinib has significant efficacy, its side effects cannot be ignored. Common adverse reactions include fever, rash, dry skin, headache, etc. In severe cases, it may cause interstitial lung disease, cardiotoxicity or venous thromboembolism. Patients need to regularly monitor liver function, heart function and platelet count to ensure the safety of treatment. Overall, trametinib provides a new treatment option for lung cancer patients with specific gene mutations, but its application must strictly follow medical regulations.

Reference materials:https://en.wikipedia.org/wiki/Trametinib